Pro Medicus Limited has secured a seven-year contract valued at A$16 million with TidalHealth, a unified healthcare network comprising three hospitals serving the Mid-Atlantic region across Delaware, Maryland, and Virginia. The deal represents a significant revenue milestone for the Melbourne-based medical imaging software company and provides tangible evidence that its cloud-first strategy is gaining commercial traction in the North American healthcare market.
The contract encompasses the full Visage 7 suite, including the viewer, workflow and open archive platforms, plus the cardiology imaging module. Implementation will be cloud-based, with rollout planning commencing immediately and a go-live target of Q1 2027. Notably, Pro Medicus has structured the deal on a transaction-based pricing model, meaning the A$16 million represents a floor rather than a ceiling, with additional upside available as TidalHealth’s usage grows.
The investment case hinges on several factors. The seven-year term provides meaningful revenue visibility in a healthcare sector where purchasing decisions are complex and contract cycles lengthy. The cloud-based deployment reinforces Pro Medicus’s positioning as the provider of choice for healthcare systems seeking to migrate imaging infrastructure away from on-premises architecture, a transition now viewed as essential in North American healthcare IT. Third, the inclusion of the cardiology module alongside core imaging products signals a customer preference for integrated solutions, a commercial shift that could unlock higher-margin revenue streams as more healthcare providers seek to consolidate their fragmented imaging estate.
Management commentary in the announcement provides additional context. CEO Dr Sam Hupert noted that TidalHealth joins a growing cohort of Visage customers opting for the cloud platform, and flagged cardiology adoption as an emerging trend. This suggests Pro Medicus may have successfully differentiated its offering not merely on technical merit, but on the breadth of its product bundling, allowing hospital systems to reduce vendor sprawl and operational complexity. The CEO also stated that pipeline strength spans all market segments and that there is growing interest in the “Full Stack” concept.
For investors, the key metrics to track going forward are the frequency of new contract announcements, the contract values achieved, and the attach rate of specialty modules like cardiology. The Q1 2027 go-live date for TidalHealth provides a natural checkpoint for assessing implementation execution risk. Beyond that, monitoring whether the cloud migration trend and specialty product bundling strategy continue to drive customer wins will be essential to determining whether Pro Medicus has identified a durable competitive advantage. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Pro Medicus Limited (ASX: PME)
Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
